SCHEMBL29449840

SCHEMBL29449840

Fc1cccc(Cl)c1C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.43
TAAR1 Q96RJ0 2/20 0.42
GAA P10253 3/20 0.39
TLR7 Q9NYK1 1/20 0.39
CYP1A2 P05177 1/20 0.36
CYP2A6 P11509 1/20 0.36
TRPA1 O75762 1/20 0.35
LMNA P02545 2/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 3/20 0.34
BACE1 P56817 1/20 0.34
HCAR1 Q9BXC0 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL936662 1.00 NOTUM (0.43) NOTUMTAAR1GAATLR7CYP1A2
SCHEMBL8722602 0.85 NOTUM (0.50) NOTUMCYP1A2CYP2A6LMNATSHR
SCHEMBL27879107 0.83 TAAR1 (0.43) TAAR1GAACYP1A2CYP2A6LMNA
SCHEMBL1541726 0.82 TRPA1 (0.40) TAAR1TRPA1TSHRHCAR1ALDH1A1
SCHEMBL802985 0.79 GAA (0.41) TAAR1GAACYP1A2CYP2A6LMNA
SCHEMBL22969778 0.76 NOTUM (0.43) NOTUMCYP1A2CYP2A6LMNATSHR
SCHEMBL1041749 0.76 NOTUM (0.43) NOTUMCYP1A2CYP2A6LMNATSHR
SCHEMBL17972850 0.76 TAAR1 (0.42) TAAR1GAALMNABACE1MEN1
SCHEMBL21718832 0.76 TAAR1 (0.38) TAAR1GAACYP1A2CYP2A6LMNA
SCHEMBL30728872 0.76 TAAR1 (0.42) TAAR1GAALMNABACE1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109153674-B Iminothiadiazine dioxide derivatives as inhibitors of plasmepsin V of plasmodium UCB生物制药有限责任公司 2022-03-22 CN disclosed
WO-2022053010-A1 FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES Janssen Sciences Ireland Unlimited Company (IE) 2022-03-17 WO disclosed